SymCel Launches Commercial Solution of Innovative Label-Free Cell-Based Assay
Symcel — the company behind the revolutionary cell-based assay tool providing real time cellular bioenergetics measurements — has announced the commercial readiness of its calScreener system, over 10 years in development. Since the technology has moved from its prototype into a fully functional commercial platform, three units have been installed at leading international research institutions with exponential growth predicted during the next few years.
The calScreener is a drug discovery tool enabling continuous monitoring of energy release from biological systems regardless of morphology. The label-free detection system provides significant cost advantages and is predicted to revolutionise drug discovery techniques. The last few years has seen a drive in drug discovery for technologies that enable more in vivo like environments. By measuring the total energy released, the calScreener system actively measures the true phenotype effect and thus a more accurate indication of pharmacodynamics, regardless of pathway or mechanism involved, as the measurement is non-invasive and non-destructive, also enables post experimental analysis of cellular contents and metabolites.
What is remarkable about this system is its flexibility of experiments, with parameters such as toxic effects, bioavailability, stability of tested compound and, ultimately, drug efficacy. Current technologies are focused on genotype performance testing, whereas calScreener is the only solution that enables a true phenotype screen.
The company has predicted significant sales across Europe in 2014, with US market launch forecast within the next year. “Already we have seen a huge demand for the calScreener as pharma companies search for more predictive models to drug discovery. The technology is the closest to in vivo testing of any commercially available product and provides far better clinical predictability in drug development. The system is adapted for 3D cell cultures and monitors tissue like behaviour and can also used for bacteria, yeast and parasites,” commented Christer Wallin, President & CEO at SymCel.
Having successfully proved the commercial viability at three sites, the company is now actively looking for partners across Europe and will design bespoke systems and installations for each customer.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance